Atea Pharmaceuticals Ownership
| AVIR Stock | USD 3.22 0.07 2.22% |
Shares in Circulation | First Issued 2017-12-31 | Previous Quarter 84.4 M | Current Value 84.5 M | Avarage Shares Outstanding 68 M | Quarterly Volatility 24.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Atea |
Atea Stock Ownership Analysis
About 72.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.63. Some equities with similar Price to Book (P/B) outperform the market in the long run. Atea Pharmaceuticals recorded a loss per share of 2.0. The entity last dividend was issued on the 9th of November 2012. The firm had 1:6 split on the 9th of November 2012. Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 63 people. For more info on Atea Pharmaceuticals please contact the company at 857 284 8891 or go to https://ateapharma.com.Besides selling stocks to institutional investors, Atea Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Atea Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Atea Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Atea Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Atea Pharmaceuticals Insider Trades History
About 12.0% of Atea Pharmaceuticals are currently held by insiders. Unlike Atea Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Atea Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Atea Pharmaceuticals' insider trades
Atea Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Atea Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Atea Pharmaceuticals backward and forwards among themselves. Atea Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Atea Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Almitas Capital Llc | 2024-12-31 | 752 K | Northern Trust Corp | 2024-12-31 | 704.9 K | Charles Schwab Investment Management Inc | 2024-12-31 | 659.5 K | Federated Hermes Inc | 2024-12-31 | 582.9 K | Newtyn Management Llc | 2024-12-31 | 580 K | Morgan Stanley - Brokerage Accounts | 567 K | Two Sigma Advisers, Llc | 2024-12-31 | 493.6 K | Jpmorgan Chase & Co | 2024-12-31 | 409.3 K | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 390.9 K | Blackrock Inc | 2024-12-31 | 9.1 M | Bml Capital Management Llc | 2024-12-31 | 7.6 M |
Atea Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atea Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atea Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atea Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Atea Pharmaceuticals Outstanding Bonds
Atea Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Atea Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Atea bonds can be classified according to their maturity, which is the date when Atea Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ATH 255 19 NOV 30 Corp BondUS04686E2U56 | View | |
| ATH 25 24 MAR 28 Corp BondUS04686E2Y78 | View | |
| ATH 345 15 MAY 52 Corp BondUS04686JAE10 | View | |
| ATH 395 25 MAY 51 Corp BondUS04686JAD37 | View | |
| US04686JAC53 Corp BondUS04686JAC53 | View | |
| ATHENE HLDG LTD Corp BondUS04686JAA97 | View | |
| ATHENE HLDG LTD Corp BondUS04686JAB70 | View | |
| ATH 665 01 FEB 33 Corp BondUS04686JAF84 | View |
Atea Pharmaceuticals Corporate Filings
| 21st of March 2025 Other Reports | ViewVerify | |
8K | 6th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 4th of March 2025 Other Reports | ViewVerify | |
| 14th of February 2025 Other Reports | ViewVerify |
Pair Trading with Atea Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Atea Stock
| 0.68 | VINC | Vincerx Pharma Earnings Call This Week | PairCorr |
Moving against Atea Stock
| 0.57 | AZN | AstraZeneca PLC ADR | PairCorr |
| 0.57 | LLY | Eli Lilly | PairCorr |
| 0.57 | SNY | Sanofi ADR | PairCorr |
| 0.55 | GILD | Gilead Sciences | PairCorr |
| 0.44 | BMY | Bristol Myers Squibb | PairCorr |
The ability to find closely correlated positions to Atea Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea Pharmaceuticals to buy it.
The correlation of Atea Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.